NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Document Type:Grants NoticeFunding Opportunity Number:PAR-23-200Funding Opportunity Title:NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)Opportunity Category:DiscretionaryOpportunity Category Explanation: Funding Instrument Type:GrantCategory of Funding Activity:HealthCategory Explanation: Expected Number of Awards: CFDA Number(s):93.867 -- Vision ResearchCost Sharing or Matching Requirement:No Version:Synopsis 1Posted Date:Jun 27, 2023Last Updated Date:Jun 27, 2023Original Closing Date for Applications:Mar 16, 2025 Current Closing Date for Applications:Mar 16, 2025 Archive Date:Apr 21, 2025Estimated Total Program Funding: Award Ceiling:$500,000Award Floor: Document Type:Grants NoticeFunding Opportunity Number:PAR-23-200Funding Opportunity Title:NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)Opportunity Category:DiscretionaryOpportunity Category Explanation: Funding Instrument Type:GrantCategory of

Funding Activity:HealthCategory Explanation: Expected Number of Awards: CFDA Number(s):93.867 -- Vision ResearchCost Sharing or Matching Requirement:No Version:Synopsis 1Posted Date:Jun 27, 2023Last Updated Date:Jun 27, 2023Original Closing Date for Applications:Mar 16, 2025 Current Closing Date for Applications:Mar 16, 2025 Archive Date:Apr 21, 2025Estimated Total Program Funding: Award Ceiling:$500,000Award Floor: Eligible Applicants:Public housing authorities/Indian housing authorities For profit organizations other than small businesses Private institutions of higher education State governments Others (see text field entitled "Additional Information on Eligibility" for clarification) Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) City or township governments Small businesses Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governmentsAdditional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Agency Name:National Institutes of HealthDescription:The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.Link to Additional Information:https://grants.nih.gov/grants/guide/pa-files/PAR-23-200.htmlGrantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: NIH Grants Information grantsinfo@nih.govSee Section VII. Agency Contacts within the full opportunity announcement for all other inquires.